Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Key Points

• Representative Gilbert Ray Cisneros, Jr. recently purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), investing between $1,001 and $15,000 on July 15th.
• Ultragenyx reported a quarterly earnings per share (EPS) of ($1.17), exceeding analysts' expectations, with revenue up 13.2% compared to the previous year.
• Institutional investors currently own 97.67% of Ultragenyx's stock, signaling strong interest from larger financial entities.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on August 14th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on July 15th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of W.R. Berkley NYSE: WRB on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 7/31/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 7/31/2025.
• Sold $1,001 - $15,000 in shares of Medpace NASDAQ: MEDP on 7/24/2025.
• Sold $1,001 - $15,000 in shares of Avantor NYSE: AVTR on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Revvity NYSE: RVTY on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Gulfport Energy NYSE: GPOR on 7/18/2025.
• Purchased $1,001 - $15,000 in shares of PTC NASDAQ: PTC on 7/9/2025.
• Purchased $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 7/9/2025.

Ultragenyx Pharmaceutical Trading Up 0.6%

NASDAQ:RARE traded up $0.1740 during trading hours on Friday, hitting $29.6940. 361,990 shares of the stock were exchanged, compared to its average volume of 1,292,440. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $60.37. The firm's fifty day moving average price is $31.85 and its 200 day moving average price is $35.89. The company has a market cap of $2.86 billion, a P/E ratio of -5.38 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same period in the previous year, the business earned ($1.52) EPS. Ultragenyx Pharmaceutical's quarterly revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC lifted its stake in Ultragenyx Pharmaceutical by 638.3% during the second quarter. Headlands Technologies LLC now owns 11,983 shares of the biopharmaceutical company's stock worth $436,000 after purchasing an additional 10,360 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in Ultragenyx Pharmaceutical by 12.5% during the second quarter. CANADA LIFE ASSURANCE Co now owns 26,398 shares of the biopharmaceutical company's stock worth $962,000 after purchasing an additional 2,937 shares in the last quarter. E Fund Management Co. Ltd. lifted its stake in Ultragenyx Pharmaceutical by 9.1% during the second quarter. E Fund Management Co. Ltd. now owns 9,052 shares of the biopharmaceutical company's stock worth $329,000 after purchasing an additional 752 shares in the last quarter. Tidal Investments LLC lifted its stake in Ultragenyx Pharmaceutical by 4.7% during the second quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company's stock worth $458,000 after purchasing an additional 564 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth $9,817,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on RARE shares. Morgan Stanley dropped their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Wells Fargo & Company dropped their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Wedbush dropped their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group dropped their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Cantor Fitzgerald dropped their price target on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $81.50.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.